Drug intelligence / Profile preview

3-methyl-1,2,4-triazolyl chitosan

Development stage: Unknown
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

3-methyl-1,2,4-triazolyl chitosan (MTACS) is a synthesized chemical compound derived from acyl thiourea chitosan through a cyclization reaction. It has been developed for its enhanced antifungal properties, particularly against fungi such as Stemphylium solani weber, Alternaria porri, and Gloeosporium theae-sinensis, making it a potential agent for crop protection.

Beyond the preview

Go deeper on 3-methyl-1,2,4-triazolyl chitosan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-methyl-1,2,4-triazolyl chitosan.

Explore the full profile